The peptide sector is undergoing a profound transformation. In the early days, the core question from clients was, “Can it be made?” Today, as GLP-1 therapies and other innovative peptide drugs enter large-scale commercialization, pharmaceutical companies are looking for a peptide CDMO that can deliver consistently, compliantly, and at scale—without disruption.

The shift from technical capability to reliable delivery reflects a real-world shift in how global pharma views supply chain security. With seventeen years of experience in peptide development and manufacturing, JYMed Peptide has built the underlying infrastructure to turn the promise of high-quality, stable, and scalable delivery into a demonstrable operational capability.

Peptide CDMO Capacity That Supports Reliable Commercial Delivery

In the commercial phase, capacity is a fundamental requirement for any peptide CDMO—and the foundation of reliable delivery.

JYMed Peptide’s Hubei API manufacturing site operates 10 independent cGMP production lines, with solid- and liquid-phase reactors totaling over 30,000 litres. Current annual peptide API capacity exceeds 4 metric tons and will reach 10 metric tons in 2026. Our Shenzhen formulation facility adds 4 GMP lines, with capacity for 15 million ampoules (liquid), 10 million cartridges, and 5 million lyophilized vials per year.

This integrated, large-scale capacity helps address common client challenges – scheduling constraints, expansion bottlenecks, and the need for revalidation across multiple sites – enabling end-to-end production from peptide API to finished dosage forms, and keeping commercial supply chains running without interruption.

Compliance beyond certificates – every batch traceable and auditable

At JYMed Peptide, compliance is not a wall plaque. It is a discipline embedded across R&D, production, and QC – and reflected in batch data that withstands regulatory scrutiny.

The company has twice passed FDA cGMP on-site inspections, undergone multiple official NMPA inspections, and successfully completed a quality audit by a top-ten global pharma company, becoming a qualified peptide API supplier to that client. On data integrity and IP protection, we use electronic lab notebooks, encrypted desktop environments, and graded authorization systems – building safeguards into both systems and processes to protect client data and intellectual property.

Integrated Technology Platform – From Laboratory Development to Commercial Manufacturing

JYMed Peptide operates a full-spectrum peptide technology platform, with a 7,000 m² R&D centre and a team of over 130 dedicated scientists. Our technical coverage spans solid-phase, solution-phase, low-protecting-group strategies, hybrid peptide synthesis, continuous-flow hydrogenation, and TFA-free green chemistry – giving us the flexibility to tailor routes to each project, rather than forcing molecules into standard templates.

For long-chain peptides, cyclic peptides, complex structures, and peptide conjugates, we have established process development and scale-up expertise. To date, we have completed over 3,000 CRO projects and more than 65 CDMO projects, supported 27 IND approvals in China and the United States, and contributed to the development and commercialization of one innovative peptide drug. This volume of diverse projects translates into more robust process development, faster tech transfer, and more dependable commercial delivery.

Global regulatory capability – reducing filing risk and navigating complexity

Regulatory pathways for peptide drugs in the US, EU, and China are demanding. Impurity profiling, stability data, and method validation are frequent sources of CRLs – and delays that hit timelines directly. JYMed Peptide’s specialised regulatory team has deep familiarity with major global filing systems and end-to-end submission pathways.

Drug Master Files for key products, including semaglutide and tirzepatide, have been submitted to the FDA; oxytocin holds a European CEP; and one innovator product has been approved in China. What clients receive from JYMed Peptide is not simply an API or drug product that meets specifications – it is a mature, filing-ready delivery package designed to support global regulatory requirements.

Seventeen years of peptide expertise – a peptide CDMO you can trust

With seventeen years in peptides – and founding team experience approaching thirty years – JYMed Peptide has built expertise in the areas that matter most: technology depth, production scale, compliance rigour, and regulatory know-how. The result is an integrated capability – from early discovery and process optimization to pilot-scale manufacturing, process scale-up, commercial manufacturing, and global registration – that is documented, repeatable, and stable. The result is dependable delivery supported by systems and experience clients can trust.

JYMed Peptide – A leading global peptide solutions provider.